Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand.
- Author:
Kasem SERESIRIKACHORN
1
;
Lalita NORASETTHADA
;
Sakarin AUSAYAKHUN
;
Atitaya APIVATTHAKAKUL
;
Sirima TANGCHITTAM
;
Vannakorn PRUKSAKORN
;
Kitsada WUDHIKARN
;
Damrong WIWATWONGWANA
Author Information
- Publication Type:Original Article
- Keywords: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue; Ocular adnexal lymphoma; MALT lymphoma; Radiotherapy
- MeSH: Disease-Free Survival; Female; Humans; Lacrimal Apparatus; Lymphoma; Lymphoma, B-Cell, Marginal Zone*; Orbit; Radiotherapy; Retrospective Studies; Thailand*
- From:Blood Research 2018;53(4):307-313
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Primary ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (POML) is the most common subtype of lymphoma involving the eyes in Thailand. We sought to assess the characteristics and treatment outcomes of patients with POML in Thailand. METHODS: We retrospectively reviewed patient data and included patients diagnosed with POML between January 2004 and December 2016 at Chiang Mai University Hospital and King Chulalongkorn Memorial Hospital, Thailand. We collected and analyzed patients' clinical characteristics and treatment outcomes. RESULTS: Among 146 patients with lymphoma involving the eyes, 121 (82%) were diagnosed with POML. Sixty-four (52.9%) were women with median age 58 (range, 22–86) years. The most common presenting symptom was orbital mass (71.1%). Common sites of origin were the orbit (46.3%) and lacrimal gland (34.7%). At presentation, 22.3% of patients had bilateral eye involvement. About half of patients had stage I disease (N=59, 56.2%) and 20% had stage IV. Most patients (73.3%) had a low-risk International Prognostic Index. Radiotherapy was the main treatment for patients with limited-stage disease (66.7% in stage I and 56.5% in stage II). The overall response rate was 100% with complete response rates 80%, 77.3%, and 64.7% for stages I, II, and IV, respectively. Five-year progression-free survival (PFS) and overall survival were 66.1% and 94.0%, respectively. For patients with limited-stage disease, radiotherapy significantly improved PFS compared with treatment not involving radiotherapy (5-year PFS 89.9% vs. 37.3%, P=0.01). CONCLUSION: We revealed that POML has good response to treatment, especially radiotherapy, with excellent long-term outcome.
